This is potential with the approval of 2 new drugs, the net income for 2010 is at least 10m so is trading about 10 pe--- but they expect for 2011 a 70% growth.....so with a 2011 forward PE the stock is really cheap at this price..... i found this a very interesting stock, the only problem i foresee is a posible dilution....